Clofazimine therapy of lepromatous leprosy caused by dapsone-resistant mycobacterium leprae.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000814:Aniline Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001706:Biopsy; D003622:Dapsone / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005260:Female; D005528:Foot; D006801:Humans; D007918:Leprosy / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D008297:Male; D008722:Methods; D051379:Mice; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000302:isolation & purification; D010619:Phenazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D012867:Skin / Q000382:microbiology; D013997:Time Factors
D000814:Aniline Compounds; D010619:Phenazines; D003622:Dapsone